Exscientia, an Oxford, England, UK-based Artificial Intelligence (AI)-driven drug discovery company, raised US$26m in Series B financing round.
The round included participation from new investors Celgene Corporation and specialist healthcare investor GT Healthcare Capital Partners, as well as existing investor Evotec AG.
The company intends to use the funds to scale its pipeline and advance selected programmes towards clinical development.
Led by Professor Andrew Hopkins, CEO and founder, and Alex Snow, Executive Chairman, Exscientia is at an Artificial Intelligence (AI)-driven drug discovery and design company. Its Centaur Chemist™ platform enables productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Roche and Evotec.